BR112018071347A2 - moduladores de nlrp3 - Google Patents

moduladores de nlrp3

Info

Publication number
BR112018071347A2
BR112018071347A2 BR112018071347A BR112018071347A BR112018071347A2 BR 112018071347 A2 BR112018071347 A2 BR 112018071347A2 BR 112018071347 A BR112018071347 A BR 112018071347A BR 112018071347 A BR112018071347 A BR 112018071347A BR 112018071347 A2 BR112018071347 A2 BR 112018071347A2
Authority
BR
Brazil
Prior art keywords
nlrp3
disease
condition
disorder
compound
Prior art date
Application number
BR112018071347A
Other languages
English (en)
Inventor
James Olhava Edward
Glick Gary
Ghosh Shomir
R Roush William
Original Assignee
Innate Tumor Immunity Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Innate Tumor Immunity Inc filed Critical Innate Tumor Immunity Inc
Publication of BR112018071347A2 publication Critical patent/BR112018071347A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

a presente invenção refere-se a entidades químicas (por exemplo, um composto ou um sal farmaceuticamente aceitável, e/ou hidrato, e/ou cocristal, e/ou combinação de fármaco do composto) que modulam (por exemplo, agonizam ou agonizam parcialmente) nlrp3 que é útil, por exemplo, para tratar uma condição, doença ou distúrbio em que uma diminuição em atividade de nlrp3 (por exemplo, uma condição, doença ou distúrbio associado com sinalização de nlrp3 reprimida ou prejudicada) contribui para a patologia e/ou sintomas e/ou progressão da condição, doença ou distúrbio (por exemplo, câncer) em um indivíduo (por exemplo, um humano). esta invenção também apresenta composições, bem como, outros métodos de usar e preparar as mesmas.
BR112018071347A 2016-04-19 2017-04-19 moduladores de nlrp3 BR112018071347A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662324626P 2016-04-19 2016-04-19
US201762460519P 2017-02-17 2017-02-17
PCT/US2017/028384 WO2017184746A1 (en) 2016-04-19 2017-04-19 Nlrp3 modulators

Publications (1)

Publication Number Publication Date
BR112018071347A2 true BR112018071347A2 (pt) 2019-02-05

Family

ID=58672702

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018071347A BR112018071347A2 (pt) 2016-04-19 2017-04-19 moduladores de nlrp3

Country Status (12)

Country Link
US (2) US10556903B2 (pt)
EP (1) EP3445761A1 (pt)
JP (1) JP7104633B6 (pt)
KR (1) KR20180134395A (pt)
CN (1) CN109071535B (pt)
AU (1) AU2017252640A1 (pt)
BR (1) BR112018071347A2 (pt)
CA (1) CA3021349A1 (pt)
IL (1) IL262303A (pt)
MX (1) MX2018012249A (pt)
SG (1) SG11201809082WA (pt)
WO (1) WO2017184746A1 (pt)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017252640A1 (en) 2016-04-19 2018-12-06 Innate Tumor Immunity, Inc. NLRP3 modulators
WO2018009916A1 (en) 2016-07-07 2018-01-11 The Board Of Trustees Of The Leland Stanford Junior University Antibody adjuvant conjugates
MA46535A (fr) 2016-10-14 2019-08-21 Prec Biosciences Inc Méganucléases modifiées spécifiques de séquences de reconnaissance dans le génome du virus de l'hépatite b
TWI674261B (zh) 2017-02-17 2019-10-11 美商英能腫瘤免疫股份有限公司 Nlrp3 調節劑
BR112020000523A2 (pt) 2017-07-14 2020-07-14 Innate Tumor Immunity, Inc. moduladores de nlrp3
EA037780B1 (ru) * 2017-10-18 2021-05-20 Иннэйт Тьюмор Иммунити, Инк. Модуляторы nlrp3
CA3084582A1 (en) 2017-12-20 2019-06-27 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein
WO2019123340A1 (en) 2017-12-20 2019-06-27 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein
EP3759109B1 (en) 2018-02-26 2023-08-30 Gilead Sciences, Inc. Substituted pyrrolizine compounds as hbv replication inhibitors
JP7229565B2 (ja) 2018-03-21 2023-02-28 オラテック セラピューティクス リミティド ライアビリティ カンパニー メラノーマを治療するための方法
WO2019195181A1 (en) 2018-04-05 2019-10-10 Gilead Sciences, Inc. Antibodies and fragments thereof that bind hepatitis b virus protein x
JP7296398B2 (ja) 2018-04-06 2023-06-22 インスティチュート オブ オーガニック ケミストリー アンド バイオケミストリー エーエスシーアール，ヴイ．ヴイ．アイ． ３’３’－環状ジヌクレオチド
TWI818007B (zh) 2018-04-06 2023-10-11 捷克科學院有機化學與生物化學研究所 2'3'-環二核苷酸
TW202005654A (zh) 2018-04-06 2020-02-01 捷克科學院有機化學與生物化學研究所 ２，２，─環二核苷酸
TW201945388A (zh) 2018-04-12 2019-12-01 美商精密生物科學公司 對b型肝炎病毒基因體中之識別序列具有特異性之最佳化之經工程化巨核酸酶
KR20210005106A (ko) * 2018-04-25 2021-01-13 인네이트 튜머 이뮤니티, 인코포레이티드 Nlrp3 조정제
US20190359645A1 (en) 2018-05-03 2019-11-28 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2'3'-cyclic dinucleotides comprising carbocyclic nucleotide
CN117263952A (zh) * 2018-05-11 2023-12-22 四川科伦博泰生物医药股份有限公司 稠环化合物、其制备方法及用途
US20210269438A1 (en) * 2018-07-02 2021-09-02 Regents Of The University Of Minnesota Therapeutic compounds and methods of use thereof
US20210308140A1 (en) * 2018-07-25 2021-10-07 Novartis Ag Nlrp3 inflammasome inhibitors
WO2020028097A1 (en) 2018-08-01 2020-02-06 Gilead Sciences, Inc. Solid forms of (r)-11-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-0x0-2,3,8,13b-tetrahydro-1h-pyrido[2,1-a]pyrrolo[1,2-c] phthalazine-7-c arboxylic acid
ES2930171T3 (es) 2018-08-16 2022-12-07 Innate Tumor Immunity Inc Moduladores de NLRP3 derivados de imidazo[4,5-C]quinolina
EP3837015B1 (en) 2018-08-16 2024-02-14 Innate Tumor Immunity, Inc. Imidazo[4,5-c]quinoline derived nlrp3-modulators
JP2021534180A (ja) 2018-08-16 2021-12-09 イネイト・テューマー・イミュニティ・インコーポレイテッドInnate Tumor Immunity, Inc. 置換４−アミノ−１Ｈ−イミダゾ［４，５−ｃ］キノリン化合物およびその製造の改良法
US11203591B2 (en) 2018-10-31 2021-12-21 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds
WO2020092528A1 (en) 2018-10-31 2020-05-07 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity
WO2020093905A1 (zh) * 2018-11-07 2020-05-14 四川科伦博泰生物医药股份有限公司 并环化合物、其制备方法及用途
CN113227055A (zh) * 2018-11-16 2021-08-06 诺华股份有限公司 用于治疗与nlrp活性相关的病症的化合物和组合物
CN111253390B (zh) * 2018-11-30 2023-10-03 四川科伦博泰生物医药股份有限公司 并环化合物、其制备方法及用途
US20220089571A1 (en) 2019-01-14 2022-03-24 Innate Tumor Immunity, Inc. Nlrp3 modulators
KR20210114983A (ko) * 2019-01-14 2021-09-24 인네이트 튜머 이뮤니티, 인코포레이티드 Nlrp3 조정제
ES2930151T3 (es) * 2019-01-14 2022-12-07 Innate Tumor Immunity Inc Moduladores heterocíclicos de NLRP3, para su uso en el tratamiento del cáncer
EP3911641A1 (en) * 2019-01-14 2021-11-24 Innate Tumor Immunity, Inc. Nlrp3 modulators
CN113195469A (zh) * 2019-02-19 2021-07-30 四川科伦博泰生物医药股份有限公司 含氮并环化合物、其制备方法及用途
US20220143061A1 (en) 2019-03-07 2022-05-12 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3'3'-cyclic dinucleotides and prodrugs thereof
EP3934757B1 (en) 2019-03-07 2023-02-22 Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. 2'3'-cyclic dinucleotides and prodrugs thereof
EP3935065A1 (en) 2019-03-07 2022-01-12 Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. 3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator
WO2020190725A1 (en) 2019-03-15 2020-09-24 Bolt Biotherapeutics, Inc. Immunoconjugates targeting her2
TW202210480A (zh) 2019-04-17 2022-03-16 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
TWI751517B (zh) 2019-04-17 2022-01-01 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
EP3956446A1 (en) 2019-04-17 2022-02-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treatment of nlrp3 inflammasome mediated il-1beta dependent disorders
CN116854706A (zh) * 2019-04-18 2023-10-10 四川科伦博泰生物医药股份有限公司 稠环化合物、其制备方法及用途
US20220324927A1 (en) * 2019-05-01 2022-10-13 H. Lee Moffitt Cancer Center And Research Institute, Inc. Structure-guided engineering of peptide-based nlrp3 inflammasome inhibitors for myelodysplastic syndromes (mds)
EP3972695A1 (en) 2019-05-23 2022-03-30 Gilead Sciences, Inc. Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors
WO2021034804A1 (en) 2019-08-19 2021-02-25 Gilead Sciences, Inc. Pharmaceutical formulations of tenofovir alafenamide
CR20220129A (es) 2019-09-30 2022-05-06 Gilead Sciences Inc Vacunas para vhb y métodos de tratamiento de vhb
CN112851667B (zh) * 2019-11-28 2022-09-09 暨南大学 含氮并杂环类化合物及其药用组合物和应用
US20230031465A1 (en) 2019-12-06 2023-02-02 Precision Biosciences, Inc. Optimized engineered meganucleases having specificity for a recognition sequence in the hepatitis b virus genome
WO2021142203A1 (en) * 2020-01-10 2021-07-15 Innate Tumor Immunity, Inc. Nlrp3 modulators
CN111214662B (zh) * 2020-02-28 2022-03-22 武汉叶风生物科技有限公司 Nlrp3炎性小体的抑制剂在制备治疗垂体腺瘤的药物中的应用及治疗垂体腺瘤的药物
CA3169348A1 (en) 2020-03-20 2021-09-23 Gilead Sciences, Inc. Prodrugs of 4'-c-substituted-2-halo-2'-deoxyadenosine nucleosides and methods of making and using the same
WO2021198511A1 (en) 2020-04-03 2021-10-07 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treatment of sars-cov-2 infection
WO2022008597A1 (en) 2020-07-08 2022-01-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical composition for the treatment of infectious diseases
WO2022084300A1 (en) 2020-10-20 2022-04-28 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for diagnosis and monitoring form of coronavirus infection
TW202310852A (zh) 2021-05-13 2023-03-16 美商基利科學股份有限公司 ＴＬＲ８調節化合物及抗ＨＢＶ ｓｉＲＮＡ療法之組合
US11926628B2 (en) 2021-06-23 2024-03-12 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
AU2022298639A1 (en) 2021-06-23 2023-12-07 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
US11976072B2 (en) 2021-06-23 2024-05-07 Gilead Sciences, Inc. Diacylglycerol kinase modulating compounds
CA3220923A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1271477A (en) 1983-11-18 1990-07-10 John F. Gerster 1h-imidazo[4,5-c]quinolin-4-amines
DK0385630T3 (da) * 1989-02-27 1997-05-12 Riker Laboratories Inc 1H-imidazo(4,5-c)quinolin-4-aminer som antivirale midler
US5389640A (en) * 1991-03-01 1995-02-14 Minnesota Mining And Manufacturing Company 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines
US5268376A (en) 1991-09-04 1993-12-07 Minnesota Mining And Manufacturing Company 1-substituted 1H-imidazo[4,5-c]quinolin-4-amines
JPH1180156A (ja) 1997-09-04 1999-03-26 Hokuriku Seiyaku Co Ltd １−（置換アリール）アルキル−１ｈ−イミダゾピリジン−４−アミン誘導体
GB0023008D0 (en) 2000-09-20 2000-11-01 Glaxo Group Ltd Improvements in vaccination
US7927613B2 (en) 2002-02-15 2011-04-19 University Of South Florida Pharmaceutical co-crystal compositions
MXPA05006740A (es) 2002-12-20 2005-10-05 3M Innovative Properties Co Imidazoquinolinas arilo-sustituidas.
WO2005018555A2 (en) 2003-08-14 2005-03-03 3M Innovative Properties Company Lipid-modified immune response modifiers
KR101106812B1 (ko) 2003-08-27 2012-01-19 쓰리엠 이노베이티브 프로퍼티즈 컴파니 아릴옥시 및 아릴알킬렌옥시 치환된 이미다조퀴놀린
CN1842336A (zh) * 2003-08-27 2006-10-04 3M创新有限公司 芳氧基和芳基亚烷氧基取代的咪唑并喹啉
EA200600540A1 (ru) 2003-09-05 2006-08-25 Анадис Фармасьютикалз, Инк. Введение лигандов tlr7 и их пролекарств для лечения инфекции вируса гепатита с
JP4891088B2 (ja) 2003-11-25 2012-03-07 スリーエム イノベイティブ プロパティズ カンパニー 置換されたイミダゾ環系および方法
TW200533352A (en) 2003-12-04 2005-10-16 3M Innovative Properties Co Sulfone substituted imidazo ring ethers
US20080015184A1 (en) * 2004-06-14 2008-01-17 3M Innovative Properties Company Urea Substituted Imidazopyridines, Imidazoquinolines, and Imidazonaphthyridines
US8017779B2 (en) * 2004-06-15 2011-09-13 3M Innovative Properties Company Nitrogen containing heterocyclyl substituted imidazoquinolines and imidazonaphthyridines
US20070259881A1 (en) 2004-06-18 2007-11-08 Dellaria Joseph F Jr Substituted Imidazo Ring Systems and Methods
US7915281B2 (en) 2004-06-18 2011-03-29 3M Innovative Properties Company Isoxazole, dihydroisoxazole, and oxadiazole substituted imidazo ring compounds and method
MX2007003078A (es) 2004-09-14 2007-05-16 Novartis Vaccines & Diagnostic Compuestos de imidazoquinolina.
EP1835915A4 (en) 2004-12-30 2010-02-24 Coley Pharm Group Inc IMMUNE REACTION MODIFIER FORMULATIONS AND RELATED METHODS
JP2008532933A (ja) 2005-02-11 2008-08-21 コーリー ファーマシューティカル グループ，インコーポレイテッド 置換イミダゾキノリン類および置換イミダゾナフチリジン類
WO2006098852A2 (en) * 2005-02-23 2006-09-21 Coley Pharmaceutical Group, Inc. Hydroxyalkyl substituted imidazoquinolines
EP1851218A2 (en) 2005-02-23 2007-11-07 3M Innovative Properties Company Hydroxyalkyl substituted imidazoquinoline compounds and methods
WO2007079086A1 (en) 2005-12-28 2007-07-12 Coley Pharmaceutical Group, Inc. Pyrazoloalkyl substituted imidazo ring compounds and methods
DK1983990T3 (da) 2006-01-26 2011-07-11 Us Gov Health & Human Serv Allosteriske A3-adenosin-receptormodulatorer
WO2010088924A1 (en) 2009-02-06 2010-08-12 Telormedix Sa Pharmaceutical compositions comprising imidazoquinolin(amines) and derivatives thereof suitable for local administration
US8728486B2 (en) 2011-05-18 2014-05-20 University Of Kansas Toll-like receptor-7 and -8 modulatory 1H imidazoquinoline derived compounds
US9034336B2 (en) 2011-08-30 2015-05-19 Regents Of The University Of Minnesota Immunomodulators and immunomodulator conjugates
EP2674170B1 (en) 2012-06-15 2014-11-19 Invivogen Novel compositions of TLR7 and/or TLR8 agonists conjugated to lipids
US9295732B2 (en) 2013-02-22 2016-03-29 Invivogen Conjugated TLR7 and/or TLR8 and TLR2 polycationic agonists
JP6453855B2 (ja) 2013-05-18 2019-01-16 アドゥロ バイオテック，インク． 「インターフェロン遺伝子の刺激因子」依存性シグナル伝達を活性化するための組成物及び方法
US10654807B2 (en) 2013-12-20 2020-05-19 The University Of Kansas Toll-like receptor 8 agonists
KR102462743B1 (ko) 2014-07-09 2022-11-02 버디 바이오파마슈티칼즈, 인크. 종양 치료용 항-pd-l1 조합
CN105233291A (zh) 2014-07-09 2016-01-13 博笛生物科技有限公司 用于治疗癌症的联合治疗组合物和联合治疗方法
CN112587672A (zh) 2014-09-01 2021-04-02 博笛生物科技有限公司 用于治疗肿瘤的抗-pd-l1结合物
GB201418004D0 (en) 2014-10-10 2014-11-26 Isis Innovation Polymer adjuvant
JP2018526013A (ja) 2015-09-01 2018-09-13 イネイト・テューマー・イミュニティ・インコーポレイテッドＩｎｎａｔｅ Ｔｕｍｏｒ Ｉｍｍｕｎｉｔｙ， Ｉｎｃ． 免疫または免疫抑制性サイトカインに対する抵抗性が増大した免疫細胞およびその使用
US10730871B2 (en) 2016-01-28 2020-08-04 Regents Of The University Of Minnesota Immunomodulators and immunomodulator conjugates
AU2017252640A1 (en) 2016-04-19 2018-12-06 Innate Tumor Immunity, Inc. NLRP3 modulators

Also Published As

Publication number Publication date
WO2017184746A1 (en) 2017-10-26
US11072612B2 (en) 2021-07-27
CN109071535A (zh) 2018-12-21
KR20180134395A (ko) 2018-12-18
US10556903B2 (en) 2020-02-11
CN109071535B (zh) 2021-10-08
JP2019513809A (ja) 2019-05-30
JP7104633B2 (ja) 2022-07-21
MX2018012249A (es) 2019-02-07
JP7104633B6 (ja) 2023-12-22
US20190127367A1 (en) 2019-05-02
US20200157097A1 (en) 2020-05-21
AU2017252640A1 (en) 2018-12-06
CA3021349A1 (en) 2017-10-26
SG11201809082WA (en) 2018-11-29
IL262303A (en) 2018-12-31
EP3445761A1 (en) 2019-02-27

Similar Documents

Publication Publication Date Title
BR112018071347A2 (pt) moduladores de nlrp3
MY194054A (en) Substituted imidazo-quinolines as nlrp3 modulators
EA201891565A1 (ru) Соединения и композиции для лечения состояний, ассоциированных с активностью sting
CL2017000864A1 (es) Composiciones y métodos de uso para tratar trastornos metabólicos
BR112018000906A2 (pt) ?composto, medicamento, métodos de inibição da histona desacetilase em um mamífero, e para a profilaxia ou o tratamento de doenças, e, uso de um composto?
EA201991553A1 (ru) (аза)индол-, бензотиофен- и бензофуран-3-сульфонамиды
ECSP14026271A (es) Compuestos de indol e indazol que activan la ampk
CL2019001685A1 (es) Composiciones de aminoácidos y métodos para el tratamiento de enfermedades y trastornos musculares.
BR112016025048A2 (pt) compostos e composições como agonistas do receptor tipo toll7
BR112015024530A2 (pt) composto, métodos para tratamentos de distúrbios e de doenças e para profilaxia de distúrbios, composição farmacêutica, e, uso de um composto
BR112017008198A2 (pt) pró-fármacos de carbidopa e l-dopa e métodos de uso
CO6551721A2 (es) Moduladores de cinasa novedosos
UY39413A (es) Compuestos inhibidores de metaloenzimas
BR112016015660A2 (pt) formulação farmacêutica de neuregulina (nrg) e formulação farmacêutica liofilizada de neuregulina (nrg)
UY35276A (es) Nuevos compuestos que inhiben la actividad de Lp-PLA2
SV2016005153A (es) Compuestos y composiciones como inhibidores de la mek
UY36178A (es) Novedosos derivados de ácido heteroaril-butanoico
MX2020003961A (es) Uso de inhibidores de p38 para reducir la expresion de dux4.
BR112015004465A2 (pt) sistemas, dispositivos e métodos para fornecer terapia com orientação de imagem
ECSP17038999A (es) 4-oxo-3,4-dihidro-1,2,3-benzotriazinas como moduladores de gpr139
BR112015019873A2 (pt) inibidores macrocíclicos da lrrk2 cinase
BR112016017317A8 (pt) composto, antagonista de trpa1, medicamento, e, método para profilaxia e/ou tratamento de uma doença que envolve trpa1
NI201600021A (es) Inhibidores de rorc2 heterobicicloarilo y sus métodos de uso
BR112019002730A2 (pt) acetil-leucina, ou um sal farmaceuticamente aceitável da mesma, para uso em um método de tratamento de uma doença neurodegenetativa
BR112015019919A2 (pt) compostos bicíclicos

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]